MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • MDS Virtual Congress 2021

    The Role of the PD Diary Trainer/Reviewer in Parkinson’s Disease Clinical Trials

    C. Mañeru, S. Meyer (Barcelona, Spain)

    Objective: To examine the experience profile of PD Diary raters in clinical trials Background: The Parkinson’s Disease (PD) Home Diary (Hauser, 2000)1 is a widely…
  • MDS Virtual Congress 2021

    Therapy to Reduce dementia risk In Parkinson’s disease (TRIP): Proof-of-concept trial

    D. Pourzinal, A. Bakker, G. Byrne, K. Mcmahon, J. O'Sullivan, R. Adam, A. Lehn, D. Copland, J. Yang, G. Pontone, T. Au, R. Littleford, M. Chatfield, Z. Mari, N. Dissanayaka (Herston, Australia)

    Objective: The TRIP proof-of-concept study examines functioning of the hippocampal DG/CA3 subregion as a biomarker and therapeutic target for memory impairment in Parkinson’s Disease (PD).…
  • MDS Virtual Congress 2021

    Impact of specialized light therapy in Parkinson’s disease on MDS-UPDRS parts 1-3 subscales

    B. Wyman, S. Hendrix, S. Hennessey, S. Dickson, J. Groves, W. Croft, D. Adams (Draper, USA)

    Objective: An exploratory analysis to examine the MDS-UPDRS 1-3 subitems of PD patients who underwent specialized light therapy (SLT) to assess the breadth of impact…
  • MDS Virtual Congress 2021

    Effect of oxytocin on response inhibition in Parkinson´s disease: a pilot study

    F. Carbone, P. Ellmerer, S. Spielberger, M. Peball, V. Sidoroff, M. Ritter, K. Seppi, W. Poewe, A. Djamshidian (Innsbruck, Austria)

    Objective: To observe the effect of oxytocin (OXT) on response inhibition in Parkinson´s disease (PD) patients using dedicated saccadic tasks. Background: Cumulating evidence has shown…
  • MDS Virtual Congress 2021

    LY-487,379 alleviates parkinsonism when administered as monotherapy in the MPTP-lesioned marmoset

    I. Frouni, C. Kwan, S. Nuara, S. Belliveau, A. Hamadjida, W. Kang, D. Bédard, J. Gourdon, P. Huot (Montreal, Canada)

    Objective: To determine the effect of selective metabotropic glutamate type 2 (mGlu2) receptor positive allosteric modulation as monotherapy on parkinsonism, in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned marmoset. Background: We…
  • MDS Virtual Congress 2021

    LY-487,379 enhances the anti-parkinsonian action of a low dose of L-DOPA in the MPTP-lesioned marmoset

    C. Kwan, I. Frouni, S. Nuara, S. Belliveau, A. Hamadjida, W. Kang, D. Bédard, J. Gourdon, P. Huot (Montreal, Canada)

    Objective: To investigate the effect of selective metabotropic glutamate type 2 (mGlu2) receptor positive allosteric modulation on the anti-parkinsonian action of a low dose of…
  • MDS Virtual Congress 2021

    Effect of simultaneous mGlu2 positive allosteric modulation and orthosteric stimulation combined with 5-HT2A antagonism on psychosis-like behaviours, dyskinesia and parkinsonism in the MPTP-lesioned marmoset

    S. Nuara, J. Gourdon, P. Huot (Montreal, Canada)

    Objective: To assess the effects of concurrent metabotropic glutamate type 2 (mGlu2) positive allosteric modulation and orthosteric stimulation combined with serotonin type 2A (5-HT2A) antagonism.…
  • MDS Virtual Congress 2021

    Problems faced by Parkinson’s disease patients during COVID-19 pandemic compulsory lockdown and its management with the help of Telemedicine in a North Indian cohort

    K. Shukla, N. Sawal (Chandigarh, India)

    Objective: To study problems faced by PD patients during lockdown due lack of healthcare and medication procurement and address such problems using telemedicine via virtual…
  • MDS Virtual Congress 2021

    Safinamide Improves Pain in Parkinson´s Disease. Results from the SAFINONMOTOR Study.

    R. Yáñez, C. Labandeira, M. Cimas Hernando, I. Cabo, J. Paz González, M. Alonso Losada, M. González Palmás, C. Martínez, D. Santos García (Ourense, Spain)

    Objective: Our aim was to analyze the effectiveness of safinamide on pain in Parkinson´s disease (PD) patients from the SAFINONMOTOR (an open-label study of the…
  • MDS Virtual Congress 2021

    The effect of sleep positions on morning orthostatic hypotension in Multiple System Atrophy patients: A pilot study

    T. Prasertpan, J. Sringean, R. Bhidayasiri (Bangkok, Thailand)

    Objective: To determine the effect of sleep position on morning OH in MSA patients Background: Dysautonomia is considered as one of the most distress symptom…
  • « Previous Page
  • 1
  • …
  • 114
  • 115
  • 116
  • 117
  • 118
  • …
  • 132
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley